Frequently Asked Questions
The market is segmented based on Global In-Silico Drug Discovery Market, By Type (Software as a Service, Consultancy as a Service, Software), Type of Large Molecule (Antibodies, Proteins, Peptides, Nucleic Acids, Vectors), Workflow (Discovery, Target Identification, Reverse Docking, Bioinformatics, Protein Structure Prediction, Target Validation, Lead Discovery, Pharmacophore, Library Design, Preclinical Tests, Clinical Trials), Target Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Mental Disorders, Musculoskeletal Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, Skin Disorders, Urogenital Disorders, Autoimmune Disorders, Blood Disorders, Cardiovascular Disorders, Gastrointestinal and Digestive Disorders, Hormonal Disorders, Others), End User (Contract Research Organizations, Pharmaceutical Industry, Academic and Research Institutes, Others) - Industry Trends and Forecast to 2030.
.
The Global In Silico Drug Discovery Market size was valued at USD 3394.80 USD Billion in 2022.
The Global In Silico Drug Discovery Market is projected to grow at a CAGR of 13.6% during the forecast period of 2023 to 2030.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
